Retour au classement

Resmed Inc (RMD)

Sous-évalué
HealthcareMedical Instruments & SuppliesUnited States

Fondamental

75

Prix

$219.15

Capitalisation boursière

$32.04B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$5.65B

12 derniers mois (au 30/06/2026)

Résultat net

$1.52B

12 derniers mois (au 30/06/2026)

Flux de trésorerie libre

$1.65B

Capitaux propres totaux

$6.59B

Passif total

$2.38B

Ratio de liquidité général

3.10

Couverture des intérêts

-

Dette/EBITDA

0.40

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Cas généralSous-évalué

Juste valeur

$347.54

Prix actuel

$219.15

Marge de sécurité

+36.9%

Fourchette de juste valeur

$225.90 - $469.18

Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.

Méthodes d'estimation

Objectif de cours des analystes:$250.22
Flux de trésorerie actualisés (DCF):$650.15
Multiple de résultat (P/E):$188.04
Formule de croissance de Graham:$537.45
Valeur de la capacité bénéficiaire (EPV):$117.55
P/B justifié:$95.10
Actualisation des dividendes (Gordon):$35.11
P/FFO, les fonds provenant de l'exploitation:$191.29
Bénéfices de milieu de cycle:$183.10
Multiple sur le chiffre d'affaires:$153.05
Consensus des analystes:Acheter (13B / 12H / 2S)
Dernière surprise sur les résultats:+1.09%

Indicateurs de valorisation

Ratio P/E

21.20

ROE

23.1%

Ratio P/B

4.84

P/FCF

19.34

Marge brute

61.1%

ROIC

19.7%

Radar de rentabilité

Création de valeur (avantage concurrentiel)

ROIC

19.7%

WACC

8.5%

ROIC − WACC

+11.2 pp

Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.

Critères d'analyse fondamentale

Réussi (19)

  • EPS shows upward trend
  • EPS CAGR 15.14%
  • Price CAGR 13.41%
  • ROIC 19.7%
  • Gross Margin 61.1%
  • P/FCF 19.34
  • Debt/Equity ratio
  • Operating Margin 33.4%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 23.9%
  • Revenue Growth 5Y 12.1%
  • PEG Ratio 0.79
  • Earnings Quality (OCF/NI) 1.19
  • Share Dilution -0.8%
  • Piotroski F-Score 7/9

Échoué (7)

  • P/B Ratio 4.84
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Analyst Consensus 48% Buy
  • Earnings Surprise avg 0.8%
  • Net Margin Trend 26.9% vs 27.2%

Indisponible (2)

  • Dividend Payout NaN%
  • Interest Coverage

Score F de Piotroski

7/9

Santé financière solide

score
criteria

Qualité des bénéfices

1.19

Qualité élevée : bénéfices soutenus par la trésorerie

Dilution du capital

-0.8%

Rachat d'actions. Favorable aux actionnaires

Participations institutionnelles

Gouvernance

Équipe dirigeante

NomTitreÂge
Mr. Michael J. Farrell BE, MBA, SMCEO & Chairman53
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScDFounder, Chair Emeritus & Non-Executive Director83
Mr. Michael J. RiderChief Legal Officer & Secretary67
Mr. Brett A. SandercockAdvisor58
Mr. Justin LeongChief Product Officer47
Mr. Aaron BloomerChief Financial Officer39
Mr. Alastair RobertsonChief Information Officer-
Ms. Sallilyn SchwartzChief Investor Relations Officer-
Mr. Jim EllisChief Compliance Officer-
Ms. Yvonne-Katrin PucknatChief Marketing Officer49

Risque d'audit

1

Risque du conseil

7

Risque de rémunération

4

Risque droits des actionnaires

3

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Documents

  • Rapport annuel (10-K)

    Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.

    Déposé le 2026-08-13

    Voir le document
  • Rapport trimestriel (10-Q)

    Une mise à jour de la performance financière des trois derniers mois.

    Déposé le 2026-05-01

    Voir le document
  • Rapport d'événement important (8-K)

    Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.

    Déposé le 2026-09-01

    Voir le document

via SEC EDGAR

Historique des résultats

via SEC EDGAR

Latest News

Recent headlines for RMD, sourced from Markets Gazette.

  • 3/10/2026POSITIVE
    3 Reasons Not to Sleep on ResMed Stock

    ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.

  • 3/4/2026POSITIVE
    Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years

    ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.

via Markets Gazette